Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avenacy Announces Launch of Desmopressin Acetate for Injection in the U.S. Market
Details : The company launched desmopressin acetate for injection in the US as a therapeutic equivalent generic for DDAVP, indicated for central diabetes insipidus, hemophilia A.
Brand Name : DDAVP-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 15, 2024
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Urology
Study Phase : Approved
Sponsor : Acerus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Noctiva is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void. It is the first FDA-approved therapy for nocturia.
Brand Name : Noctiva
Molecule Type : Peptide
Upfront Cash : Undisclosed
March 09, 2022
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Urology
Highest Development Status : Approved
Sponsor : Acerus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Urology
Study Phase : Approved
Sponsor : Acerus Pharmaceuticals
Deal Size : $16.0 million
Deal Type : Agreement
Acerus Announces Definitive Agreement to Acquire Serenity LLC and The Global Rights To NOCTIVA™
Details : Both Noctiva™ and Natesto® are highly clinically differentiated products with significant patent protection into the 2030s, that Acerus management feels could reach double-digit market share in each of these large market opportunities.
Brand Name : Noctiva
Molecule Type : Peptide
Upfront Cash : $6.0 million
February 28, 2022
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Urology
Highest Development Status : Approved
Sponsor : Acerus Pharmaceuticals
Deal Size : $16.0 million
Deal Type : Agreement
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Urology
Study Phase : Approved
Sponsor : Antares Pharma
Deal Size : $25.0 million
Deal Type : Licensing Agreement
Antares Pharma Enters Exclusive License Agreement With Ferring Pharmaceuticals for Nocdurna® in U.S.
Details : This license agreement for NOCDURNA expands Antares Pharma's urology portfolio, which already includes XYOSTED, the best-selling branded testosterone replacement product in the United States.
Brand Name : Nocdurna
Molecule Type : Large molecule
Upfront Cash : $5.0 million
October 01, 2020
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Urology
Highest Development Status : Approved
Sponsor : Antares Pharma
Deal Size : $25.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?